Reactive oxygen species contribute to sleep apnea-induced hypertension in rats

Carmen M. Troncoso Brindeiro,1 Ana Q. da Silva,1,2 Kyan J. Allahdadi,1 Victoria Youngblood,1 and Nancy L. Kanagy1

1Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico; and 2Departamento de Fisiología e Biofísica, Instituto de Ciencias Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

Submitted 19 February 2007; accepted in final form 29 August 2007

Troncoso Brindeiro CM, Silva AQ, Allahdadi KJ, Youngblood V, Kanagy NL. Reactive oxygen species contribute to sleep apnea-induced hypertension in rats. Am J Physiol Heart Circ Physiol 293: H2971–H2976, 2007. First published August 31, 2007; doi:10.1152/ajpheart.00219.2007.—In clinical studies, sleep apnea is associated with hypertension, oxidative stress, and increased circulating endothelin-1 (ET-1). We previously developed a model of sleep apnea by exposing rats to eucapnic intermittent hypoxia (IH-C) during sleep, which increases both blood pressure and plasma levels of ET-1. Because similar protocols in mice increase tissue and plasma markers of oxidative stress, we hypothesized that IH-C generation of reactive oxygen species (ROS) contributes to the development of ET-1-dependent hypertension in IH-C rats. To test this, male Sprague-Dawley rats were instrumented with indwelling blood pressure telemeters and drank either plain water or water containing the superoxide dismutase mimetic, Tempol (4-hydroxy-2,2,6,6-tetramethyl-piperidine-1-oxyl, 1 mM). Mean arterial pressure (MAP) and heart rate (HR) were recorded for 3 control days and 14 treatment days with rats exposed 7 h/day to IH-C or air/air cycling (Sham). On day 14, MAP in IH-C rats treated with Tempol (107 ± 2.29 mmHg) was significantly lower than untreated IH-C rats (118 ± 9 mmHg, P < 0.05). Tempol did not affect blood pressure in sham-operated rats (Tempol = 101 ± 3, water = 101 ± 2 mmHg). Immuno reactive ET-1 was greater in plasma from IH-C rats compared with plasma from sham-operated rats but was not different from Sham in Tempol-treated IH-C rats. Small mesenteric arteries from IH-C rats but not Tempol-treated IH-C rats had increased superoxide levels as measured by ferric cytochrome c reduction, lucigenin signaling, and dihydroethidium fluorescence. The data show that IH-C increases ET-1 production and vascular ROS levels and that scavenging superoxide prevents both. Thus oxidative stress appears to contribute to increases in ET-1 production and elevated arterial pressure in this rat model of sleep apnea-induced hypertension.

Tempol; endothelin

THE REPEATED EPISODES OF CESATION of breathing that occur during sleep apnea have been linked to the increased generation of reactive oxygen species (ROS) with an associated increase in cardiovascular morbidity (1). Since it is estimated that up to one in five adults in Western countries suffer from sleep apnea (36), this condition appears to be a significant cause of cardiovascular disease.

Several longitudinal studies of sleep apnea patients conclude that the greatest health risk of sleep apnea is the increased incidence of cardiovascular disease (24, 42), with the most consistent alteration being increased mean arterial pressure (MAP) (26, 30). Thus almost 50% of people suffering from sleep apnea also suffer from hypertension (13), and it is of great relevance to better understand the role of oxidative stress in sleep apnea-associated hypertension.

Repeated apneic episodes are reported to increase oxidative stress in sleep apnea patients (16, 21), in animal models of sleep apnea (31, 41), and in cultured cells exposed to cyclical hypoxia (43). However, debate continues on the consequences of this elevated oxidative stress. One potential consequence is an increased production of the potent vasoconstrictor, endothelin 1 (ET-1), which can be induced by ROS (18).

A role for ET-1 in sleep apnea-associated cardiovascular disease is further suggested by increased circulating plasma ET-1 (32, 44), which is reversed when apneic episodes are prevented with continuous positive airway pressure (17). Previously, we have shown that in rats with simulated sleep apnea, circulating plasma ET-1 increases in parallel with increases in arterial pressure and that blocking ET-1 receptors lowers MAP in these rats (20). Therefore, the mechanistic link between sleep apnea, increased ET-1 synthesis, and hypertension may be oxidative stress.

Free radicals have previously been shown to play a role in endothelial dysfunction and ET-1 synthesis in hypertension. Kaehler et al. (18) and Cheng et al. (4, 5) have reported that ROS, specifically superoxide, increase prepro-ET-1 promoter activity. We therefore hypothesized that ET-1 production is stimulated by increased ROS generation during the intermittent periods of hypoxia associated with sleep apnea, leading to ET-dependent systemic hypertension.

We tested this hypothesis by measuring ROS in arteries from eucapnic intermittent hypoxia (IH-C) and sham-operated rats and by scavenging ROS with the antioxidant, Tempol (4-hydroxy-2,2,6,6-tetramethyl-piperidine-1-oxyl, a superoxide dismutase mimetic) during IH-C treatment in rats and by determining the effect on blood pressure and circulating ET-1.

MATERIALS AND METHODS

Animal model. Animal protocols for this study were approved by the Institutional Animal Care and Use Committee of the University of New Mexico and follow the National Institutes of Health guidelines for animal use in research. Male Sprague-Dawley rats (200–250 g body wt; Harlan, Indianapolis, IN) were instrumented with indwelling
blood pressure telemeters (DSI model PA-C40; Arden Hills, MN), allowing daily recording of MAP and heart rate (HR). Telemeter devices were sutured to the abdominal cavity wall, and the catheter tip was advanced into the abdominal aorta via the femoral artery. Control hemodynamic recordings were initiated 5 days after the surgery.

**Intermittent hypoxia/eucapnia protocol.** After recovery, rats (n = 26) were randomly divided into either IH-C (n = 15) or air-exposed (Sham; n = 13) groups. Sham animals were exposed to the same environmental factors as IH-C, except the gas in the chamber was always air (21% O₂). Vehicle-treated IH-C (n = 9) and Sham rats (n = 7) drank tap water, whereas Tempol-treated rats drank water containing Tempol throughout the treatment period (1 mM, n = 6/group). This dose of Tempol has previously been shown to prevent increases in oxidative stress in ET-1-infused rats (34, 38). The atmosphere in the IH-C chamber was controlled by electronically regulated solenoid switches in a three-channel gas mixer, which gradually lowered oxygen in the chamber over 90 s from 21% to ~5% O₂ and increased the CO₂ content from 0% to ~5% (Technolutions). Chambers were rapidly flushed with room air for the following 90 s to restore O₂ to ~21% and CO₂ to 0%. Rats were exposed to 20 IH-C cycles/h for 7 d/day during their sleep period for 14 days.

**Measurement of superoxide with ferricytochrome c.** The amount of superoxide generated in mesenteric arterioles was measured by the reduction of ferricytochrome c using a kinetic spectrophotometer (DU 530; Beckman, Fullerton, CA). Reduction of ferricytochrome c by O₂⁻ increases absorbance at 550 nm and can be used as a quantitative measure of O₂⁻ production (33). Absorbance at 550 nm was recorded every minute for 10 min before and 35 min after addition of a freshly isolated single mesenteric vascular tree to PBS containing ferricytochrome c (5 × 10⁻⁵ M, RT). A second branch of approximately equal weight (0.49 ± 0.02 mg average wt) was added to a second cuvette containing the SOD mimetic, tiron (10 μM). The difference in A₅₅₀ in the absence and presence of tiron was used to estimate O₂⁻ generation/arteriole segment.

**Lucigenin assay.** Small mesenteric arteries were collected from rats anesthetized with pentobarbital sodium (150 mg/kg ip) on day 14 of treatment. Arteries were placed in cold physiological saline solution (PSS), (containing in mM) 129.8 NaCl, 5.4 KCl, 0.83 MgSO₄, 1.9 NaHCO₃, 1.8 CaCl₂, and 5.5 glucose and then transferred to a test tube containing lucigenin in HEPES-buffered saline (1 mmol, pH 7.4, room temperature). Background luminescence of the solution without arteries was subtracted from basal and NADPH-stimulated (0.1 mM) luminescence for each sample. Measurements were normalized for the arteries was subtracted from basal and NADPH-stimulated (0.1 mM) luminescence for each sample. Measurements were normalized for the dry weight of arteries.

**Dihydroethidium staining.** The superoxide-sensitive fluorescent dye, dihydroethidium (DHE), was used to evaluate in situ production of superoxide. DHE is freely permeable to cells and, in the presence of O₂⁻, is oxidized to the fluorescent products, 2-hydroxyethidium and ethidium⁺ (45, 46). DHE fluorescence is thus a qualitative way to determine relative levels of oxidative stress (45). Fixed small mesenteric arteries from IH-C and Sham rats were rapidly frozen in optimum cutting temperature (OCT) embedding compound (TissueTek) and stored at −70°C until assayed. Sections (10 μm) from IH-C and Sham arteries were thaw-mounted onto glass slides and dried 30 min at room temperature. Sections were then covered with DHE in PBS (10 μM) and incubated 45 min at 37°C. Slides were washed with PBS, and coverslips were mounted using Vectashield. Slides were analyzed on a Nikon Epifluorescence microscope using the Chroma TRITC filter set to illuminate at 510–560 nm and to collect emissions at 570–650 nm, a range that detects primarily DNA-bound ethidium⁺ and not the 2-OH-ethidium product of superoxide and DHE (46). Image density was analyzed using Metamorph software. Average integrated intensities in three sections/artery were averaged from one artery per rat for four IH-C and four Sham rats.

**ET-1 assay.** An ET-1 selective ELISA kit (QuantiGlo; R & D Systems, Minneapolis, MN) was used to measure the concentration of ET-1 in plasma samples collected from anesthetized IH-C and Sham animals on day 14. Blood was drawn into EGTA-coated vacutainer tubes and centrifuged at 3,000 g at 4°C for 10 min. Plasma was stored frozen at −70°C until the assay was performed. This assay employs the quantitative sandwich enzyme immunoassay technique with a monoclonal antibody specific for ET-1 precoated onto a microplate. Standards (0.34 to 250 pg/ml) and samples were analyzed in triplicate following the instructions in the kit. The minimum detectable concentration reported by the manufacturer is 0.1 pg/ml and the average variation within samples at 3.4%. In our assay with three replicates, the intra-assay precision was 8% for the standard curve and 10% for the samples, and values in control rats (1.26 ± 0.08 pg/ml) were in the range previously reported in rats (37).

**Statistical analysis.** All data are expressed as means ± SE. Data were compared using two-way repeated-measures analysis of variance (ANOVA) or a one-way ANOVA followed by a Student-Newman-Keuls’s post hoc test as appropriate (SigmaStat 3.0). Differences were considered significant for P < 0.05.

**RESULTS**

**Hemodynamic measurements.** MAP and HR were not different during the baseline recording period between the four groups. However, after 14 days of treatment, there was a significant difference in MAP between the IH-C/vehicle group (118 ± 8.8 mmHg) and the other three groups: Sham/vehicle (101 ± 1.7), Sham/Tempol (101 ± 3.1), and IH-C/Tempol (107 ± 2.3 mmHg) (Fig. 1). In the Tempol-treated IH-C rats, MAP was not significantly different from that in the Sham groups. Heart rate did not differ between any of the four groups, did not change over the time of treatment, and was not different between groups at day 14: Sham/vehicle 392 ± 3.5, Sham/Tempol 372 ± 38.7, IH-C/vehicle 395 ± 3.1, and IH-C/Tempol 391 ± 14.8 beats/min.

**Superoxide generation.** Superoxide (O₂⁻) generation measured by cytochrome c reduction was significantly greater in arteries from the IH-C group compared with the Sham group (Fig. 2). There was no difference between arteries from Sham and IH-C rats treated in vivo with Tempol.

**ROS-activated luminescence.** Basal measurements of ROS, using lucigenin as a detector, were significantly greater in arteries from the IH-C arteries than in the Sham arteries when normalized for tissue dry weight (luminescence/tissue wt in mg). NADPH stimulated a large increase in luminescence.
cence in both groups, and the difference between groups was even greater than in the absence of NADPH (Fig. 3).

DHE staining. Arteries from IH-C rats had greater DHE-induced fluorescence than arteries from Sham rats (Fig. 4). Fluorescence in arteries from IH-C rats treated with Tempol was not different from that in Sham arteries. This indicates that there is greater ROS generation in the vascular wall following 14 days of IH-C exposure but that the increase is prevented by in vivo Tempol treatment.

Plasma ET-1. The calculated concentration of immunoreactive ET-1 in plasma samples from the IH-C rats was greater than that in the Sham rat samples (Fig. 5). However, the concentration in the samples from the IH-C rats drinking Tempol-containing water was not different from that in the Sham rats. Plasma ET-1 was also not different between Sham rats drinking water and those drinking water with Tempol. Thus IH-C increases circulating ET-1, and Tempol specifically reduces ET-1 in IH-C rats. This suggests that Tempol prevents IH-C-induced hypertension, in part, by decreasing ET-1 synthesis.

DISCUSSION

Sleep apnea is a growing health problem in the United States, and many studies have reported a significant association between cardiovascular disease and sleep apnea (7, 14, 15). Hypertension has the strongest correlation with ~50% of sleep apnea patients also having hypertension (25). Because the increased risk of mortality in patients with obstructive sleep apnea (OSA) is largely from cardiovascular incidents, understanding the mechanisms underlying the cardiovascular pathology of this condition will allow more directed interventions to prevent permanent or lethal damage. Although corrective therapies to prevent the repeated apneas during sleep reduce the increased cardiovascular complications of OSA, compliance...
tion-induced hypocapnia (22). This is in contrast to studies by rats where exposure to hypoxia only with hyperventilation
slightly slower than the increase in arterial pressure in an elevation in arterial pressure by than in studies where only IH was used (11), with a significant our model of IH-C, arterial pressure increases more rapidly in vivo generation of ROS, specifically O2
Furthermore, studies by Xu et al. (41) demonstrated that IH intermittent eucapnic hypoxia, vascular ROS generation, ET-1 our data are the first to provide an in vivo association between IH-C increases MAP, plasma ET-1, and vascular ROS levels
plasma ET-1 in blood samples taken from rats exposed to 14 days of either Sham or IH-C cycling and drinking either tap water or water containing Tempol (1 mmol/l). [ET-1] was significantly greater in plasma from IH-C rats compared with plasma from sham-operated rats and plasma from Tempol-treated IH-C rats (P < 0.05). *Signif-
Fig. 5. Plasma concentration of endothelin (ET-1) in blood samples taken from rats exposed to 14 days of either Sham or IH-C cycling and drinking either tap water or water containing Tempol (1 mmol/l). [ET-1] was significantly greater in plasma from IH-C rats compared with plasma from sham-operated rats and plasma from Tempol-treated IH-C rats (P < 0.05). *Significance difference from Sham; #Significant difference from vehicle within group.

continues to be low (8), and a practical approach to further reduce cardiovascular disease in OSA patients would be to effectively treat the hypertension. Previous studies examining the mechanisms linking hypertension to OSA have shown that ROS (9, 16) are increased in patients and in animal models of OSA (41). ROS have also been associated with increased ET-1 levels and MAP. The novel findings in this study are that J) IH-C increases MAP, plasma ET-1, and vascular ROS levels and 2) the SOD mimetic Tempol prevents the increase in MAP, oxidative stress, and plasma ET-1 in IH-C-exposed rats. Thus our data are the first to provide an in vivo association between intermittent eucapnic hypoxia, vascular ROS generation, ET-1 production, and blood pressure regulation.

We have previously shown that IH-C exposure in rats increases arterial pressure in an ET-1-dependent manner (20). Furthermore, studies by Xu et al. (41) demonstrated that IH increases ROS levels in several brain regions, whereas Peng et al. (27) demonstrated an association between oxidative stress and hypertension in mice exposed to intermittent hypoxia. The current study further establishes that during IH-C exposure, in vivo generation of ROS, specifically O2−, is increased and appears to be necessary to develop ET-1-dependent hypertension.

In this model, rats are exposed 20 times/h to hypoxia with CO2 supplementation for 7 h/day, a rate comparable with the number of oxygen desaturation events in patients with moderate sleep apnea (3). This protocol differs from some experimental models of OSA that do not include exposure to CO2. In our model of IH-C, arterial pressure increases more rapidly than in studies where only IH was used (11), with a significant elevation in arterial pressure by day 10 of exposure. This is slightly slower than the increase in arterial pressure in an earlier study in which we used indwelling arterial catheters and tethers to record blood pressure (20), suggesting the stress of a tether system may accelerate the onset of hypertension. However, in both studies, maintaining eucapnia appears to accelerate the development of hypertension compared with studies where rats were exposed to hypoxia only with hyperventilation-induced hypocapnia (22). This is in contrast to studies by Fletcher and coworkers (12, 22), who saw no chronic effect on blood pressure by supplementing IH with CO2, a protocol similar to ours that maintains eucapnia (22). However, in the previous studies, the exposure protocol had very rapid IH cycling (2 cycles/min), and arterial PO2 did not return to control levels before the start of the next hypoxia exposure (2). Thus our IH-C protocol produces blood-gas changes more similar to those reported in clinical studies of OSA (6) and may be more relevant to the human condition where sleep apnea is correlated with an increased incidence of hypertension (28).

In the earlier studies by Fletcher and coworkers (12), blood pressure was recorded at day 0 and after 35 days exposure to either 120 episodes/h of hypoxia only (inspired O2, 2.5%) or hypoxia supplemented with CO2 (8% or 14% compared with 5% in our studies). These earlier studies did not measure blood pressure at earlier time points in the IH-C groups but did observe that the acute increase in blood pressure and sympathetic nerve activity was greater with IH-C than with IH exposure (22). It is therefore interesting to speculate that added CO2 may accelerate humoral and neural responses to IH, similar to observations that hypercapnic hypoxia in humans produces a more profound activation of the sympathetic nervous system than IH only (23).

Similar to a previous study using the IH-C protocol (20), plasma ET-1 levels in untreated IH-C rats were significantly higher than in Sham rats. Furthermore, the increase in circulating ET-1 and in blood pressure during IH-C exposure was prevented by simultaneous administration of the superoxide dismutase mimetic, Tempol. In contrast, Tempol had no effect on MAP or plasma ET-1 in Sham rats. Therefore Tempol appears to counteract an IH-C-exposure effect, perhaps by eliminating ROS-stimulated ET-1 production (5, 19), as suggested by the measures of vascular ROS. Thus our data suggest that in vivo oxidative stress in IH-C rats, and potentially OSA patients, contributes to the development of hypertension by stimulating ET-1 synthesis.

Three separate indicators measured increased ROS production in small mesenteric arteries from IH-C rats compared with arteries from sham-operated rats. Because ET-1 can activate NADPH oxidase (29), it is possible that elevated ET-1 stimulated ROS production in the vascular wall of IH-C rats. This would suggest the increased ROS results from ET-1 receptor activation. However, it is unclear how a feed-forward system might operate in vivo with ET-1 production both stimulated by superoxide and increasing superoxide production. Furthermore, the observation that the O2− scavenger, Tempol, prevented both increases in circulating ET-1 and IH-C-induced increases in MAP makes it more likely that the increase in ROS is upstream of ET-1 generation rather than downstream.

Previous studies of ET-1-dependent hypertension have demonstrated that Tempol lowers blood pressure and ROS production (35), that it lowers vascular ROS production without decreasing blood pressure (10), or that it decreases blood pressure independent of its effects on superoxide production (40). For example, Xu et al. (39) suggested that Tempol decreases MAP through direct inhibition of sympathetic neurons in the cardiovascular system. This may have contributed to the decrease in the MAP we observed and would be in agreement with previous studies demonstrating that blocking the sympathetic nervous system inhibits the development of
hypertension in other protocols of IH-C exposure (22). Because the in vivo treatment with Tempol lowered both the vascular ROS generation and the increases in ET-1 and MAP, the data also support the hypothesis that ROS act at the level of the vascular wall to stimulate ET-1 production, which in turn elevates MAP. Therefore, additional studies with ET-1 receptor antagonists are needed to establish which is the sequence of events.

In conclusion, the cellular mechanisms connecting sleep apnea to ROS generation and subsequent hypertension are not entirely clear. The current studies provide a novel potential link, suggesting repetitive exposures to brief periods of eucapnic hypoxia lead to increased vascular ROS generation, elevated circulating ET-1, and the development of hypertension. Thus it appears that, in this model of OSA, production of ROS contributes to both the synthesis of ET-1 and to the development of hypertension.

ACKNOWLEDGMENTS

This study was supported by NIH Grants PA-5642 and HL-03852.

GRANTS

N. L. Kanagy is an Established Investigator of the American Heart Association and C. M. Troncoso Brindeiro was a MARK-U-STAR Fellow through the National Institutes of Health (NIH). Special thanks to Roma Kalra for assistance with the endothelin assay.

REFERENCES


